{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:48:01Z","timestamp":1761518881969,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.3816\/cbc.2002.n.036","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:04:50Z","timestamp":1221080690000},"page":"333-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Phase II Trial of Doxorubicin\/Docetaxel\/Cyclophosphamide for Locally Advanced and Metastatic Breast Cancer: Results from NSABP Trial BP-58"],"prefix":"10.3816","volume":"3","author":[{"given":"Roy E.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stewart J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron P.","family":"Scholnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit M.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl G.","family":"Kardinal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry C.","family":"Lembersky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftherios P.","family":"Mamounas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2002.n.036_bib1","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/jnci\/87.15.1169","article-title":"Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines","volume":"87","author":"Gianni","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CBC.2002.n.036_bib2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/JCO.1995.13.5.1152","article-title":"Paclitaxel as second and subsequent chemotherapy for metastatic breast cancer: activity independent of prior anthracycline response","volume":"13","author":"Seidman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib3","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1200\/JCO.1994.12.8.1621","article-title":"Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I\/II trial of 96-hour infusion","volume":"12","author":"Wilson","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib4","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","article-title":"Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer","volume":"13","author":"Ravdin","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/oxfordjournals.annonc.a058907","article-title":"A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group","volume":"5","author":"Ten Bokkel Huinink","year":"1994","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib6","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1200\/JCO.1995.13.12.2886","article-title":"Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer","volume":"13","author":"Valero","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib7","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib8","first-page":"101a","article-title":"Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)","volume":"17","author":"Henderson","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib9","unstructured":"Henderson IC. 2000 NIH Consensus Development Conference on Adjuvant Breast Cancer Treatment; November 1-3, 2000; Bethesda, MD."},{"key":"10.3816\/CBC.2002.n.036_bib10","unstructured":"Mamounas EP. 2000 NIH Consensus Development Conference on Adjuvant Breast Cancer Treatment; November 1-3, 2000; Bethesda, MD."},{"key":"10.3816\/CBC.2002.n.036_bib11","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dosefinding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/oxfordjournals.annonc.a010717","article-title":"Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic","volume":"7","author":"Gehl","year":"1996","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2001.19.2.314","article-title":"Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer","volume":"19","author":"Nabholtz","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib14","first-page":"84","article-title":"Doxorubicin and docetaxel (AT) is superior to standard doxorubicin and cyclophosphamide (AC) as 1st line CT for MBC: randomized phase III trial","volume":"57","author":"Nabholtz","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2002.n.036_bib15","first-page":"17","article-title":"Docetaxel in combination with doxorubicin: a phase I dose-finding study","volume":"11","author":"Dieras","year":"1997","journal-title":"Oncol (Huntingt)"},{"key":"10.3816\/CBC.2002.n.036_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1026418831238","article-title":"Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer","volume":"10","author":"Misset","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib17","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2000.18.12.2369","article-title":"Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196","volume":"18","author":"Sparano","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib18","first-page":"34","article-title":"Combination docetaxel\/cyclophosphamide in patients with advanced solid tumors","volume":"11","author":"Valero","year":"1997","journal-title":"Oncol (Huntingt)"},{"key":"10.3816\/CBC.2002.n.036_bib19","first-page":"35a","article-title":"Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC)","volume":"21","author":"Mackey","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib20","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.3816\/CBC.2002.n.036_bib21","series-title":"Statistical Methods","first-page":"120","author":"Snedecor","year":"1980"},{"key":"10.3816\/CBC.2002.n.036_bib22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Amer Stat Assoc"},{"key":"10.3816\/CBC.2002.n.036_bib23","series-title":"Survival analysis: techniques for censored and truncated data","first-page":"109","author":"Klein","year":"1997"},{"key":"10.3816\/CBC.2002.n.036_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/gyno.1994.1279","article-title":"Comparative studies of taxol and taxotere on tumor growth and lymphocyte functions","volume":"55","author":"Munkarah","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00000421-200010000-00007","article-title":"Cellular immune profile of patients with advanced cancer before and after taxane treatment","volume":"23","author":"Tong","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib26","first-page":"3766","article-title":"In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells","volume":"6","author":"Zeng","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2002.n.036_bib27","first-page":"2597","article-title":"Docetaxel enhances the cytotoxicity of tetrahydropyranylaadriamycin in a sequence-dependent manner","volume":"21","author":"Egawa","year":"2001","journal-title":"Anticancer Res"},{"key":"10.3816\/CBC.2002.n.036_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/taap.1999.8847","article-title":"Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart","volume":"163","author":"Platel","year":"2000","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.3816\/CBC.2002.n.036_bib29","first-page":"16","article-title":"Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations","volume":"25","author":"D'Incalci","year":"1998","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/sonc.2001.26435","article-title":"Pharmacokinetic profiles of doxorubicin in combination with taxanes","volume":"28","author":"Holmes","year":"2001","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2002.n.036_bib31","first-page":"104a","article-title":"Phase II trial of doxorubicin and docetaxel for locally advanced and metastatic breast cancer: preliminary results from NSABP BP-57","volume":"19","author":"Lembersky","year":"2000","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911702646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911702646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:07:08Z","timestamp":1761512828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911702646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["S1526820911702646"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2002.n.036","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2002,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Trial of Doxorubicin\/Docetaxel\/Cyclophosphamide for Locally Advanced and Metastatic Breast Cancer: Results from NSABP Trial BP-58","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2002.n.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}